• About
  • Subscribe
  • Advertise
  • Contact
Saturday, February 14, 2026
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home

We need to talk about choice

by Staff Writer
January 5, 2018
in Company updates & acquisitions
Reading Time: 4 mins read
A A
Share on FacebookShare on Twitter

Therefore, there is a very real danger that the changes – which will limit patient choice – could slip through without proper debate. What if the power of big name insurers like Bupa is too great to counter?What if the politicians and media owners risk losing too much by antagonising these corporate giants who collectively spend $190 million per year on lobbying and advertising, buying th a lot of influence and column inches?I would encourage everyday consumers to take a close look at what is afoot. Bupa, Australia’s largest health insurer, is about to make a fundamental change to Private Health Insurance (PHI), the likes of which has never been seen before in Australia.From August, Bupa proposes to limit the choice of fully insured surgical care to those hospitals contracted to it and which form part of the Bupa network.Under this proposal if a Bupa policy holder (a patient) chooses a surgeon that is not operating at a Bupa contracted centre, they will receive only the bare minimum of legislated insurance cover. In short it will leave th with a large out-of-pocket expense.{{quote-A:R-W:450-Q: In breaking the current paradigm of PHI, it may be that Bupa has released a genie which gives a new momentum for reforming the health syst. }}This change is set to affect approximately 30% of day surgeries. Day surgeries often form part of the fabric of convenient local health communities. Bupa is claiming the change will ensure a medical service with minimal to zero out-of-pocket cost (but only if you go via their network of care). In essence this change is about limiting choice.AMA President Dr Michael Gannon has likened the Bupa changes to “a big leap towards US style Managed Care”. Managed Care is a term often loosely used, but in essence it describes the syst in the USA where privately insured patients ‘belong’ to a PHI and the network of medical providers who are contracted to it. In the USA, patients who want full choice must go outside their insurer and pay out-of-pocket for the medical and hospital services they procure. We are very lucky in Australia to have enjoyed full choice from all insurers. Until now.So, what is more important to a patient? Choice when it comes to their surgical care, or out-of-pocket costs? It would be fair to say that both are relevant and it may be that being locked in to the Bupa network is the way patients choose to go. But this is a very big and very risky business decision Bupa is making. If successful it will almost certainly lead to increased profits for Bupa and the possibility that other private health insurers will adopt similar policies.In a country like Australia, where choice of doctor is a fundamental benefit of private health insurance, one must seriously question whether patients will rain with Bupa or switch to a health fund that does allow fully insured choice. The future is uncertain and this experiment in health insurance will be closely watched. For those patients who struggle to pay their private health prium every month it is also a valid reason to lose faith in private health cover and seek an alternative.Recently the concept of ‘Health Saver Accounts’ (HSA) has been suggested. Self Managed Super Funds (SMSF) allow for tax efficient retirent savings and HSA could work in a similar way. Basic mathatics suggests that over a 30-year period of invested contribution, one would easily save more than $100,000 if private health priums were invested. Clearly this is not enough for catastrophic or severe chronic illness which is why the public syst rains a safety net. However for elective surgery of a more routine nature it would likely be sufficient.Let’s be imaginative. The taxation revenue foregone by a 15% concession could be funded from the PHI rebate, which the Federal Government already contributes up to 30% of insurance costs to at a cost of $6 billion dollars annually. One might argue that $6 billion would be better in a patient’s HSA than the profit sheet of a health insurer. The HSA could be topped up, passed on in a will, used for a family mber or bequeathed to a Federal HSA ‘Future Fund’.In breaking the current paradigm of PHI, it may be that Bupa has released a genie which gives a new momentum for reforming the health syst and making best use of the $6 billion PHI rebate. Perhaps the PHI rebate is a policy which is past its use by date. It was legislated 20 years ago by John Howard, before Medibank and NIB floated on the stock market, and before Bupa came to Australia where it now makes more than 40% of its global profit…before that simpler time when health insurers were operating as not-for-profit.Private health insurers are now more profitable than banks on a return for equity basis and when a company such as Bupa breaks a traditional model we are right to reassess the whole ‘box and dice’ and openly discuss imaginative health reforms for the future.


Name: Peter SumichQualifications: MBBS, FRANZCOWorkplace: Hunter Street Eye SpecialistsPosition: OphthalmologistLocation: ParramattaYears in the practice: 17

 

Related Posts

The International Red Light Ophthalmic Society (IRLOS) was formerly launched at the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress. Image: Eyerising

APAO 2026: Red light therapy moves into the global spotlight

by Staff Writer
February 13, 2026

The 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress, held on 5–8 February 2026 in Hong Kong, marked a defining moment...

A Belgian firm has taken a big stake in Rayner. Image: Rayner.

Firm spending $840 million for big stake in Rayner

by Rob Mitchell
February 11, 2026

Belgian investment holding company Groupe Bruxelles Lambert (GBL) is investing €500 million (AU$840  million) in British ophthalmic manufacturer Rayner. An...

Melbourne-based BHG Capital has reportedly agreed a 50% stake in Two Svge. Image: vichie81/stock.adobe.com.

Investor takes big stake in up-and-coming WA eyewear company

by Staff Writer
February 10, 2026

Victorian fund BGH Capital has reportedly taken a nearly 50% stake in Perth-born Two Svge, a direct-to-consumer supplier of bold...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2026 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2026 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited